Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2014, New Report Launched
Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Leber Congenital Amaurosis (LCA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leber Congenital Amaurosis (LCA) and special features on late-stage and discontinued projects.
View full press release